Nephrolithiasis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Nephrolithiasis. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Nephrolithiasis receives a directional score of 59/100, combining unmet need (74/100), competitive intensity (96/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Formation of stones in the KIDNEY.

The reproducible record is Patsnap disease ID 701c8dafae644b938d7e82c0467959fc and MeSH identifier D053040. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Age-Period-Cohort Analysis on Long-Term Mortality Trend of Genitourinary Diseases — China, 1987–2021 Age-Period-Cohort Analysis on Long-Term Mortality Trend ofGenitourinary Diseases — China, 1987–2021

Ayodele OE, Alebiosu CO. Burden of chronic kidney disease: an international perspective. Adv Chronic Kidney Dis 2010;17(3):215 − 24. http://dx.doi.org.libproxy1.nus.edu.sg/10.1053/j.ackd.2010.02.001. 1. Wang Q, Wang Y, Yang C, Wang JW, Shi Y, Wang HB, et al. Trends of urolithiasis in China: a national study based on hospitalized patients from 2013 to 2018. Kidney Dis 2023;9(1):49 − 57. http://dx.doi.org.libproxy1.nus.edu.sg/ 10.1159/000527967. 2. Zheng XY, Guo C. Strengthening systematic research on aging: reflections from an omics perspective. China CDC Wkly 2022;4(39): 875 − 8. http://dx.doi.org.libproxy1.nus.edu.sg/10.46234/ccdcw2022.181. 3. Zheng XY, Luo YN, Su BB, He P, Guo C, Tian YH, et al. Developmental gerontology and active population aging in China. China CDC Wkly 2023;5(8):184 − 7. http://dx.doi.org.libproxy1.nus.edu.sg/10.46234/ ccdcw2023.033. 4. Su BB, Zhong PL, Xuan YD, Xie JQ, Wu Y, Chen C, et al. Changing patterns in cancer mortality from 1987 to 2020 in China. Cancers 5.

Review source

Epidemiology evidence 2: Epidemiological Profile of Chronic Wounds in an Indian Population: A Community-Based Cross-Sectional Observational Study

Keywords: chronic disease epidemiology, chronic wounds, community health and primary health care research, healthcare burden, non-healing wounds, prevalence Introduction The burden of chronic wounds is substantial and frequently underestimated by the patient, the medical community, and society at large [1]. It would be better to call these wounds that fail to heal, not just because of time frame but due to various underlying mechanisms, "complex wounds" [2,3]. According to a preliminary literature review, there is currently no recent data on their prevalence and their exact impact on the quality of life (QoL), especially in the Indian scenario [2,3]. There was a relative lack of current, high- quality data on the number of people suffering from chronic non-healing wounds, the number of resources used by health agencies to manage wounds, and the kind of care provided to those whose wounds are causing them to become unwell [3]. All people experience wounds, and most of them heal without any complications. However, a significant percentage of individuals suffer from wounds that either never heal at all or heal very slowly [4,5]. The focus of the research was on these more serious wounds, which are primarily handled by community nurses and dressers. The most common types of chronic wounds are leg ulcers (mainly from venous and/or arterial disease), pressure ulcers (from unrelieved pressure as a result of immobility), and diabetic foot ulcers (DFUs) (from venous or arterial and neurological diseases) [1-3]. Another area of study that comprises modern epidemiology is the examinat

Review source

Epidemiology evidence 3: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• PH incidence is somewhat higher in females than males: 1 study using claims data found that 61% of patients with PH diagnosis were female,142, and another found that post-VTE PH cumula­ tive incidence was higher in females than males (3.9% [95% CI, 3.8%–4.1%] and 3.2% [95% CI, 3.0%–3.3%], respectively)144; females have at least a 3-fold higher prevalence of PAH both in hospital­ ized patients145 and in the outpatient setting.146 • Data from the US kidney transplantation regis­ try observed a PH prevalence of 8.2% before the transplantation.147 The cumulative incidence after 3 years after transplantation was 10.6% (95% CI, 10.3%–11.0%). • Among ≈600 000 Medicare patients admitted with acute exacerbated chronic obstructive pulmonary disease, secondary PH diagnosis was present in 10.9%.148 Lifetime Risk and Cumulative Incidence • In a US health care claim database study involving ≈170 000 patients after a VTE between 2011 and 2018144: – The 1-, 2-, and 5-year cumulative incidence of CTEPH was 2.09% (95% CI, 2.01%–2.17%), 3.54% (95% CI, 3.43%–3.65%), and 7.24% (95% CI, 7.01%–7.48%), respectively. – In individuals with a PE diagnosis, the 1-, 2-, and 5- year cumulative incidence of CTEPH was 3.82% (95% CI, 3.68%–3.97%), 6.24% (95% CI, 6.03%–6.45%), and 12.12% (95% CI, 11.69%–12.56%), respectively. Risk Factors • Risk factors are implicit in the WHO disease clas­ sification of the 5 mechanistic subtypes of PH. The most common risk factors are left-sided HD and lung disease. In patients with WHO group I PH, a 10-year analysis from HCUP data found a high prevalence of congestive

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Nephrolithiasis, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Nephrolithiasis thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The mechanism anchor is SLC12A3, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 1497 registered studies.

• NCT07780409 — Flexible Ureteroscopy for Large Renal Stones in Children; Completed; Not Applicable; sponsor Cairo University; enrollment 90.
• NCT07773090 — Role of Pre-stenting Before Retrograde Intrarenal Surgery With Miniaturized Flexible Ureteroscopes; Recruiting; Not Applicable; sponsor Al-Azhar University; enrollment 270.
• NCT07772830 — Preoperative Anxiety in Patients Undergoing RIRS and PCNL; Completed; Not Applicable; sponsor Samsun Education And Research Hospital; enrollment 120.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate SLC12A3 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Nephrolithiasis merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Nephrolithiasis is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.